IN8BIO INC. - COMMON STOCK

0,3078

13-февраля-25 11:36:11

15 мин. задержка

Акции

+0,0169

+5,81%

Сегодняшний диапазон

0,2950 - 0,3345

ISIN

N/A

Источник

NASDAQ

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

11 фев 2025 08:00:00 Источник Nasdaq GlobeNewswire
IN8bio to Present at Biotech Showcase 2025 in San Francisco

06 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

10 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

02 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

25 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

12 ноя 2024 16:26:01 Источник Nasdaq GlobeNewswire
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

12 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

05 ноя 2024 09:00:00 Источник Nasdaq GlobeNewswire
IN8bio Announces Pricing of $12.4 Million Private Placement

01 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

04 сен 2024 16:01:00 Источник Nasdaq GlobeNewswire
IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

29 авг 2024 06:05:00 Источник Nasdaq GlobeNewswire
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

12 авг 2024 08:05:00 Источник Nasdaq GlobeNewswire
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

08 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

24 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

13 июн 2024 16:01:00 Источник Nasdaq GlobeNewswire
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

03 июн 2024 06:05:00 Источник Nasdaq GlobeNewswire
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

24 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

23 май 2024 17:00:00 Источник Nasdaq GlobeNewswire
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

14 май 2024 10:00:00 Источник Nasdaq GlobeNewswire
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

13 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.